AstraZeneca Cuts 600 US Sales Jobs in $1.5B Savings Push
AstraZeneca cut about 600 U.S. respiratory and immunology sales jobs under its $1.5B savings plan, as Breztri grew just 2% and Airsupra fell 3% in Q3.
TAG K-4995 · 486 words on the filing

Summary of findings
- AstraZeneca cut ~600 U.S. respiratory and immunology commercial jobs under a $1.5B savings plan targeting 2029.
- Breztri Q3 U.S. sales rose 2% YoY to $170M despite an April asthma label expansion; Airsupra fell 3% to $43M.
- AZ pulled back its U.S. partnership with contract sales organization Syneos Health.
- CEO Pascal Soriot said the overhaul is 'reallocation of resources,' not net workforce reduction.
- Management maintains its $80 billion 2030 sales target despite LOE pressure and failures for Wainua and volrustomig.
AstraZeneca has cut roughly 600 jobs from its U.S. respiratory and immunology commercial teams, Bloomberg reports, making the unit the first visible casualty of the company's $1.5 billion cost-savings program launched in October.
Not everyone affected will walk out the door. Some employees are expected to be reassigned to other positions within the company, per the report.
Which products did the cut teams support?
At least a portion of the staffers were detailing the asthma drugs Breztri and Airsupra, both of which have stalled in the market. Breztri, despite an FDA label expansion in April from COPD into asthma, grew U.S. sales just 2% year over year in the third quarter, to $170 million. Biopharmaceuticals business chief Ruud Dobber said on the Q3 earnings call that the new indication has seen "rapid uptake."
Airsupra fared worse. The two-drug inhaler booked only $43 million in U.S. Q3 sales, down 3% year over year.
The rising star in AZ's respiratory and inflammatory portfolio is Tezspire, partnered with Amgen. The first-in-class TSLP-targeted biologic recently aced a phase 3 trial in eosinophilic esophagitis and is aiming for a third indication beyond asthma and chronic rhinosinusitis with nasal polyps.
Beyond internal cuts, AZ also pulled back its partnership with contract sales organization Syneos Health in the U.S., according to Bloomberg.
How does this square with 'no net job losses'?
The restructuring, launched in October, targets $1.5 billion in annual savings by 2029, with resources redirected toward pipeline growth. On a press call, CFO Aradhana Sarin said the overhaul will not produce a net reduction in AstraZeneca's workforce.
"You don't spend $1.5 billion without creating jobs," CEO Pascal Soriot said on the same call. "So right there, you see that there will be changes. It's more reallocation of resources across the pipeline and across the world. In the end, we are still a growing company, and the idea is not to shrink the company. The opposite, actually."
The U.S. respiratory cuts are unlikely to be the last. Sarin framed the three-year plan as a rebalancing exercise, not a single-area trim: "There will definitely be some impact in certain areas," she said, "but there'll also be growth opportunities, reskilling, upskilling of employees, opportunities for new roles, and this is all in different areas."
What's driving the squeeze?
AstraZeneca has expanded significantly under Soriot. It was one of only three large pharmas to consistently grow its workforce since 2021, according to a recent Fierce Pharma tally.
But multiple key losses of market exclusivity are creeping up on the company. A handful of high-profile clinical failures have added wrinkles too, including the Ionis-partnered heart disease candidate Wainua and volrustomig, the PD-1xCTLA-4 bispecific cancer program. Management still maintains it's on track to hit $80 billion in sales by 2030.
via Fierce Pharma (Google News) (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- V-8604
- K-1191
- V-8592
- T-7849
- V-5532